STOCK TITAN

Invivyd Inc - IVVD STOCK NEWS

Welcome to our dedicated news page for Invivyd (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Invivyd's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Invivyd's position in the market.

Rhea-AI Summary
Invivyd, Inc. to present at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
conferences
-
Rhea-AI Summary
Invivyd, Inc. appoints William Duke as Chief Financial Officer to support the company's growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
management
-
Rhea-AI Summary
Invivyd reports positive Phase 1 VYD222 clinical trial data, plans to initiate a pivotal clinical trial for potential EUA submission. Cash position of $298.4 million to support operations into Q4 2024. Conference call scheduled for August 10th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
earnings
Rhea-AI Summary
Invivyd, Inc. (IVVD) to Host Conference Call to Discuss Q2 2023 Financial Results and Business Highlights
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
management
-
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
earnings
Invivyd Inc

Nasdaq:IVVD

IVVD Rankings

IVVD Stock Data

527.68M
45.63M
20.8%
76.9%
1.38%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Waltham

About IVVD

adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.